Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)

The main objective of this trial is to explore the activity of chlorambucil, an alkylating agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA, including

  • 0 views
  • 26 Jan, 2021
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter …

small molecule
mycophenolate
tumor necrosis factor
immunosuppressive agents
panuveitis
  • 140 views
  • 14 Jul, 2022
  • 19 locations
Preoperative CRT With Capecitabine Temozolomide in Patients With LARC

This is a prospective biomarker-stratified, randomised phase II study of preoperative CRT with temozolomide plus capecitabine in patients with locally advanced rectal cancer. The primary endpoint is pathologic complete response rates defined as total regression of the primary tumor. For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will …

  • 26 views
  • 27 Jan, 2021
  • 1 location
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (ELM-2)

including an anti-CD20 antibody and an alkylating agent 3 according to Lugano Classification and as assessed by independent central review and local investigator evaluation

alkylating agent
marginal zone lymphoma
b-cell lymphoma
follicular lymphoma
tositumomab
  • 69 views
  • 07 Oct, 2022
  • 130 locations
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

marginal zone lymphoma
refractory follicular lymphoma
follicular lymphoma
ct scan
ejection fraction
  • 204 views
  • 04 Oct, 2022
  • 126 locations
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or …

temozolomide
whole-brain radiotherapy
maintenance treatment
rituximab
methotrexate
  • 0 views
  • 13 May, 2022
  • 35 locations
Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells

that cyclophosphamide (CYC) is effective for IIM-ILD and tends to be used in rapidly progressive interstitial lung diseaseRP-ILDor refractory ILD. However, CYC is an alkylating agent with many toxic

pulmonary fibrosis
fibrosis
forced vital capacity
lupus
tacrolimus
  • 0 views
  • 30 Nov, 2021
  • 1 location
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation (AGIR)

(IDHm glioma) have a better prognosis compared to the IDH wild type counterparts, they invariably recur after standard treatment with radiotherapy and alkylating agent. IDH mutation results in the

  • 0 views
  • 07 Oct, 2022
  • 1 location
Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn …

residual tumor
remission
immunosuppressive agents
myeloid leukemia
refractory acute myeloid leukemia (aml)
  • 43 views
  • 07 Oct, 2022
  • 7 locations
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers

alkylating agent, which causes DNA damage by alkylating guanine at position O6 also has activity in relapsed SCLC, particularly for brain metastases. Preliminary evidence indicates that disruption

lung carcinoma
lung cancer
immunosuppressive
metastasis
topotecan
  • 100 views
  • 27 Oct, 2022
  • 1 location